Transglutaminase 2 as a therapeutic target for neurological conditions

References

• Quinn BR, Yunes-Medina L, Johnson GVW. Transglutaminase 2: friend or foe? The discordant role in neurons and astrocytes. J Neurosci Res. 2018 Jul;96(7):1150–1158.
   PubMed Web of Science ®Google Scholar
• Eckert RL, Kaartinen MT, Nurminskaya M, et al. Transglutaminase regulation of cell function. Physiol Rev. 2014 Apr;94(2):383–417.
   PubMed Web of Science ®Google Scholar
• Gundemir S, Colak G, Tucholski J, et al. Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 2012 Feb;1823(2):406–419.
   PubMed Web of Science ®Google Scholar
• Karpuj MV, Becher MW, Steinman L. Evidence for a role for transglutaminase in Huntington’s disease and the potential therapeutic implications. Neurochem Int. 2002 Jan;40(1):31–36.
   PubMed Web of Science ®Google Scholar
• Lesort M, Chun W, Johnson GV, et al. Tissue transglutaminase is increased in Huntington’s disease brain. J Neurochem. 1999 Nov;73(5):2018–2027.
   PubMed Web of Science ®Google Scholar
• Citron BA, SantaCruz KS, Davies PJ, et al. Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer’s disease. J Biol Chem. 2001 Feb 2;276(5):3295–3301.
   PubMed Web of Science ®Google Scholar
• Johnson GV, Cox TM, Lockhart JP, et al. Transglutaminase activity is increased in Alzheimer’s disease brain. Brain Res. 1997 Mar 21;751(2):323–329.
   PubMed Web of Science ®Google Scholar
• Andringa G, Lam KY, Chegary M, et al. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson’s disease. FASEB J. 2004 May;18(7):932–934.
   PubMed Web of Science ®Google Scholar
• Junn E, Ronchetti RD, Quezado MM, et al. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2047–2052.
   PubMed Web of Science ®Google Scholar
• Wilhelmus MM, Verhaar R, Andringa G, et al. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson’s disease brain. Brain Pathol. 2011 Mar;21(2):130–139.
   PubMed Web of Science ®Google Scholar
• Festoff BW, SantaCruz K, Arnold PM, et al. Injury-induced “switch” from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord. J Neurochem. 2002 May;81(4):708–718.
   PubMed Web of Science ®Google Scholar
• Tolentino PJ, DeFord SM, Notterpek L, et al. Up-regulation of tissue-type transglutaminase after traumatic brain injury. J Neurochem. 2002 Feb;80(4):579–588.
   PubMed Web of Science ®Google Scholar
• Tolentino PJ, Waghray A, Wang KK, et al. Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats. J Neurochem. 2004 Jun;89(5):1301–1307.
   PubMed Web of Science ®Google Scholar
• van Strien ME, De Vries HE, Chrobok NL, et al. Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration. Brain Behav Immun. 2015;50:141–154.
   PubMed Web of Science ®Google Scholar
• van Strien ME, Drukarch B, Bol JG, et al. Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration? Brain Pathol. 2011 Jan;21(1):44–54.
   PubMed Web of Science ®Google Scholar
• Lu S, Saydak M, Gentile V, et al. Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem. 1995 Apr 28;270(17):9748–9756.
   PubMed Web of Science ®Google Scholar
• Jang GY, Jeon JH, Cho SY, et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene. 2010 Jan 21;29(3):356–367.
   PubMed Web of Science ®Google Scholar
• Monsonego A, Shani Y, Friedmann I, et al. Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J Biol Chem. 1997 Feb 7;272(6):3724–3732.
   PubMed Web of Science ®Google Scholar
• Tucholski J, Roth KA, Johnson GV. Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. J Neurochem. 2006 Apr;97(2):582–594.
   PubMed Web of Science ®Google Scholar
• Filiano AJ, Tucholski J, Dolan PJ, et al. Transglutaminase 2 protects against ischemic stroke. Neurobiol Dis. 2010 Sep;39(3):334–343.
   PubMed Web of Science ®Google Scholar
• Colak G, Johnson GV. Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobiol Dis. 2012 Mar;45(3):1042–1050.
   PubMed Web of Science ®Google Scholar
• Monteagudo A, Feola J, Natola H, et al. Depletion of astrocytic transglutaminase 2 improves injury outcomes. Mol Cell Neurosci. 2018 Oct;92:128–136.
   PubMed Web of Science ®Google Scholar
• Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003 Feb;4(2):140–156.
   PubMed Web of Science ®Google Scholar
• Keillor JW, Clouthier CM, Apperley KYP, et al. Acyl transfer mechanisms of tissue transglutaminase. Bioorg Chem. 2014;57:186–197.
   PubMed Web of Science ®Google Scholar
• Achyuthan KE, Greenberg CS. Identification of a guanosine triphosphate-binding site on Guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem. 1987 Feb 5;262(4):1901–1906.
   PubMed Web of Science ®Google Scholar
• Stamnaes J, Pinkas DM, Fleckenstein B, et al. Redox regulation of transglutaminase 2 activity. J Biol Chem. 2010 Aug 13;285(33):25402–25409.
   PubMed Web of Science ®Google Scholar
• Jang TH, Park HH. Crystallization and preliminary X-ray crystallographic studies of transglutaminase 2 in complex with Ca2+. Acta Crystallogr F Struct Biol Commun. 2014 Apr;70(Pt 4):513–516.
   PubMedGoogle Scholar
• Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A. 2002 Mar 5; 99(5):2743–2747.
   PubMed Web of Science ®Google Scholar
• Pinkas DM, Strop P, Brunger AT, et al. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007 Dec;5(12):e327.
   PubMed Web of Science ®Google Scholar
• Pardin C, Roy I, Lubell WD, et al. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase. Chem Biol Drug Des. 2008 Sep;72(3):189–196.
   PubMed Web of Science ®Google Scholar
• Colak G, Keillor JW, Johnson GV. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PloS One. 2011 Jan 31;6(1):e16665.
   PubMed Web of Science ®Google Scholar
• Caron NS, Munsie LN, Keillor JW, et al. Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells. PloS One. 2012;7(8):e44159.
   PubMed Web of Science ®Google Scholar
• Keillor JW, Chica RA, Chabot N, et al. The bioorganic chemistry of transglutaminase - from mechanism to inhibition and engineering. Can J Chem. 2008 Apr;86(4):271–276.
   Web of Science ®Google Scholar
• Kerr C, Szmacinski H, Fisher ML, et al. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Oncogene. 2017 May 25;36(21):2981–2990.
   PubMed Web of Science ®Google Scholar
• Badarau E, Collighan RJ, Griffin M. Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids. 2013 Jan;44(1):119–127.
   PubMed Web of Science ®Google Scholar
• Keillor JW, Apperley KY. Transglutaminase inhibitors: a patent review. Expert Opin Ther Pat. 2016;26(1):49–63.
   PubMed Web of Science ®Google Scholar
• Keillor JW, Apperley KY, Akbar A. Inhibitors of tissue transglutaminase. Trends Pharmacol Sci. 2015 Jan;36(1):32–40.
   PubMed Web of Science ®Google Scholar
• Keillor JW, Chabot N, Roy I, et al. Irreversible inhibitors of tissue transglutaminase. Adv Enzymol Relat Areas Mol Biol. 2011;78:415–447.
   PubMedGoogle Scholar
• Song M, Hwang H, Im CY, et al. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors. J Med Chem. 2017 Jan 26;60(2):554–567.
   PubMed Web of Science ®Google Scholar
• Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol. 2005 Apr;12(4):469–475.
   PubMed Web of Science ®Google Scholar
• Watts RE, Siegel M, Khosla C. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem. 2006 Dec 14;49(25):7493–7501.
   PubMed Web of Science ®Google Scholar
• de Macedo P, Marrano C, Keillor JW. Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg Med Chem. 2002 Feb;10(2):355–360.
   PubMed Web of Science ®Google Scholar
• Marrano C, de Macedo P, Gagnon P, et al. Synthesis and evaluation of novel dipeptide-bound 1,2,4-thiadiazoles as irreversible inhibitors of Guinea pig liver transglutaminase. Bioorg Med Chem. 2001 Dec;9(12):3231–3241.
   PubMed Web of Science ®Google Scholar
• Akbar A, McNeil NMR, Albert MR, et al. Structure-activity relationships of potent, targeted covalent inhibitors that abolish both the transamidation and GTP binding activities of human tissue transglutaminase. J Med Chem. 2017 Sep 28;60(18):7910–7927.
   PubMed Web of Science ®Google Scholar
• Wityak J, Prime ME, Brookfield FA, et al. SAR development of lysine-based irreversible inhibitors of Transglutaminase 2 for Huntington’s disease. ACS Med Chem Lett. 2012 Dec 13;3(12):1024–1028.
   PubMed Web of Science ®Google Scholar
• Wodtke R, Hauser C, Ruiz-Gomez G, et al. N(epsilon)-Acryloyllysine Piperazides as irreversible inhibitors of Transglutaminase 2: synthesis, structure-activity relationships, and pharmacokinetic profiling. J Med Chem. 2018 May 24;61(10):4528–4560.
   PubMed Web of Science ®Google Scholar
• Wodtke R, Wodtke J, Hauser S, et al. Development of an (18) F-LabeledIrreversible inhibitor of Transglutaminase 2 as radiometric tool for quantitative expression profiling in cells and tissues. J Med Chem. 2021 Mar 25;64(6):3462–3478.
   PubMed Web of Science ®Google Scholar
• Hausch F, Halttunen T, Maki M, et al. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem Biol. 2003 Mar;10(3):225–231.
   PubMedGoogle Scholar
• Schuppan D, Maki M, Lundin KEA, et al. A randomized trial of a Transglutaminase 2 inhibitor for Celiac disease. N Engl J Med. 2021 Jul 1;385(1):35–45.
   PubMed Web of Science ®Google Scholar
• Prime ME, Andersen OA, Barker JJ, et al. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington’s disease. J Med Chem. 2012 Feb 9;55(3):1021–1046.
   PubMed Web of Science ®Google Scholar
• Prime ME, Brookfield FA, Courtney SM, et al. Irreversible 4-Aminopiperidine Transglutaminase 2 inhibitors for Huntington’s disease. ACS Med Chem Lett. 2012 Sep 13;3(9):731–735.
   PubMed Web of Science ®Google Scholar
• Chrobok NL, Bol J, Jongenelen CA, et al. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. PloS One. 2018;13(4):e0196433.
   PubMed Web of Science ®Google Scholar
• Badarau E, Wang Z, Rathbone DL, et al. Development of potent and selective tissue Transglutaminase Inhibitors: their effect on TG2 function and application in pathological conditions. Chem Biol. 2015 Oct 22;22(10):1347–1361.
   PubMedGoogle Scholar
• Fell S, Wang Z, Blanchard A, et al. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors. Amino Acids. 2021 Feb;53(2):205–217.
   PubMed Web of Science ®Google Scholar
• Kahlem P, Terre C, Green H, et al. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14580–14585.
   PubMed Web of Science ®Google Scholar
• Miller ML, Johnson GV. Transglutaminase cross-linking of the tau protein. J Neurochem. 1995 Oct;65(4):1760–1770.
   PubMed Web of Science ®Google Scholar
• Gundemir S, Colak G, Feola J, et al. Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Biochim Biophys Acta. 2013 Jan;1833(1):1–10.
   PubMed Web of Science ®Google Scholar
• Gundemir S, Johnson GV. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PloS One. 2009 Jul 1;4(7):e6123.
   PubMed Web of Science ®Google Scholar
• Katt WP, Antonyak MA, Cerione RA. Opening up about tissue Transglutaminase: when conformation matters more than enzymatic activity. Med One. 2018;3:6.
   Google Scholar
• Singh G, Zhang J, Ma Y, et al. The different conformational states of tissue transglutaminase have opposing affects on cell viability. J Biol Chem. 2016 Apr 22;291(17):9119–9132.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Abraham C, Ihara Y. Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci U S A. 1982 Oct;79(19):6070–6074.
   PubMed Web of Science ®Google Scholar
• Zemaitaitis MO, Kim SY, Halverson RA, et al. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2003 Feb;62(2):173–184.
   PubMed Web of Science ®Google Scholar
• Ebashi M, Ito Y, Uematsu M, et al. How to demix Alzheimer-type and PSP-type tau lesions out of their mixture -hybrid approach to dissect comorbidity. Acta Neuropathol Commun. 2019 May 6;7(1):71.
   PubMedGoogle Scholar
• Shoeibi A, Olfati N, Litvan I. Frontrunner in translation: progressive supranuclear palsy. Front Neurol. 2019;10:1125.
   PubMed Web of Science ®Google Scholar
• Nemes Z, Devreese B, Steinert PM, et al. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer’s neurofibrillary tangles. FASEB J. 2004 Jul;18(10):1135–1137.
   PubMedGoogle Scholar
• Singer SM, Zainelli GM, Norlund MA, et al. Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer’s disease. Neurochem Int. 2002 Jan;40(1):17–30.
   PubMed Web of Science ®Google Scholar
• Johnson GV, LeShoure R Jr. Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity. J Neurosci Methods. 2004 Apr 30;134(2):151–158.
   PubMed Web of Science ®Google Scholar
• Wilhelmus MM, de Jager M, Smit AB, et al. Catalytically active tissue transglutaminase colocalises with Abeta pathology in Alzheimer’s disease mouse models. Sci Rep. 2016 Feb;3(6):20569.
   Google Scholar
• Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012 Oct;181(4):1426–1435.
   PubMed Web of Science ®Google Scholar
• Ward SM, Himmelstein DS, Lancia JK, et al. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans. 2012 Aug;40(4):667–671.
   PubMedGoogle Scholar
• Zempel H, Luedtke J, Kumar Y, et al. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 2013 Nov 13;32(22):2920–2937.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jung YH, Choi GE, et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis. Cell Death Differ. 2021 Jan;28(1):184–202.
   PubMed Web of Science ®Google Scholar
• McConoughey SJ, Basso M, Niatsetskaya ZV, et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med. 2010 Sep;2(9):349–370.
   PubMed Web of Science ®Google Scholar
• Citron BA, Suo Z, SantaCruz K, et al. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int. 2002 Jan;40(1):69–78.
   PubMed Web of Science ®Google Scholar
• Vermes I, Steur EN, Jirikowski GF, et al. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson’s disease indicating apoptosis. Mov Disord. 2004 Oct;19(10):1252–1254.
   PubMed Web of Science ®Google Scholar
• Grosso H, Woo JM, Lee KW, et al. Transglutaminase 2 exacerbates alpha-synuclein toxicity in mice and yeast. FASEB J. 2014 Oct;28(10):4280–4291.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grosso Jasutkar H, Yan R, et al. Transglutaminase 2 depletion attenuates alpha-synuclein mediated toxicity in Mice. Neuroscience. 2020 Aug 10;441:58–64.
   PubMed Web of Science ®Google Scholar
• Segers-Nolten IM, Wilhelmus MM, Veldhuis G, et al. Tissue transglutaminase modulates alpha-synuclein oligomerization. Protein Sci. 2008 Aug;17(8):1395–1402.
   PubMed Web of Science ®Google Scholar
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993 Mar 26;72(6):971–983.
   PubMed Web of Science ®Google Scholar
• Green H. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell. 1993 Sep 24;74(6):955–956.
   PubMed Web of Science ®Google Scholar
• DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997 Sep 26;277(5334):1990–1993.
   PubMed Web of Science ®Google Scholar
• Kahlem P, Green H, Djian P. Transglutaminase action imitates Huntington’s disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell. 1998 Mar;1(4):595–601.
   PubMed Web of Science ®Google Scholar
• Chun W, Lesort M, Tucholski J, et al. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J Cell Biol. 2001 Apr 2;153(1):25–34.
   PubMed Web of Science ®Google Scholar
• Konno T, Morii T, Hirata A, et al. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry. 2005 Feb 15;44(6):2072–2079.
   PubMed Web of Science ®Google Scholar
• Konno T, Morii T, Shimizu H, et al. Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J Biol Chem. 2005 Apr 29;280(17):17520–17525.
   PubMed Web of Science ®Google Scholar
• Bailey CD, Johnson GV. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington’s disease mouse model via aggregate-independent mechanisms. J Neurochem. 2005 Jan;92(1):83–92.
   PubMed Web of Science ®Google Scholar
• Mastroberardino PG, Iannicola C, Nardacci R, et al. ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington’s disease. Cell Death Differ. 2002 9;Sep(9):873–880.
   Google Scholar
• Menalled LB, Kudwa AE, Oakeshott S, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington’s disease. PloS One. 2014;9(6):e99520.
   PubMed Web of Science ®Google Scholar
• Lin Y, He H, Luo Y, et al. Inhibition of transglutaminase exacerbates polyglutamine-induced neurotoxicity by increasing the aggregation of mutant ataxin-3 in an SCA3 Drosophila model. Neurotox Res. 2015 Apr;27(3):259–267.
   PubMed Web of Science ®Google Scholar
• Schaertl S, Prime M, Wityak J, et al. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen. 2010 Jun;15(5):478–487.
   PubMedGoogle Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017. 3. Mar(7):42717.
   Google Scholar
• Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016 Jun 6;11(11):1117–1121.
   PubMed Web of Science ®Google Scholar
• Jeitner TM, Pinto JT, Cooper AJL. Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo. Biosci Rep. 2018 Oct 31;38(5).
   PubMedGoogle Scholar
• Palanski BA, Cystamine KC. Disulfiram inhibit human Transglutaminase 2 via an oxidative mechanism. Biochemistry. 2018 Jun 19;57(24):3359–3363.
   PubMed Web of Science ®Google Scholar
• Lesort M, Lee M, Tucholski J, et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem. 2003 Feb 7;278(6):3825–3830.
   PubMed Web of Science ®Google Scholar
• Mao Z, Choo YS, Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington’s disease knock-in striatal cells. Eur J Neurosci. 2006 Apr;23(7):1701–1710.
   PubMed Web of Science ®Google Scholar
• Bailey CD, Johnson GV. The protective effects of cystamine in the R6/2 Huntington’s disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging. 2006 Jun;27(6):871–879.
   PubMed Web of Science ®Google Scholar
• Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington’s disease. J Neurosci. 2002 Oct 15;22(20):8942–8950.
   PubMed Web of Science ®Google Scholar
• Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002 Feb;8(2):143–149.
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk JM, Pearson J, Cd B, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem. 2005 Oct;95(1):210–220.
   PubMed Web of Science ®Google Scholar
• Arbez N, Roby E, Akimov S, et al. Cysteamine protects neurons from mutant Huntingtin toxicity. J Huntingtons Dis. 2019;8(2):129–143.
   PubMed Web of Science ®Google Scholar
• Verny C, Bachoud-Levi AC, Durr A, et al. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington’s disease. Mov Disord. 2017 Jun;32(6):932–936.
   PubMed Web of Science ®Google Scholar
• van Strien ME, Breve JJ, Fratantoni S, et al. Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration? PloS One. 2011;6(9):e25037.
   PubMed Web of Science ®Google Scholar
• Chrobok NL, Bol J, Wilhelmus MMM, et al. Tissue Transglutaminase appears in monocytes and macrophages but not in lymphocytes in white matter multiple sclerosis lesions. J Neuropathol Exp Neurol. 2019 Jun 1;78(6):492–500.
   PubMed Web of Science ®Google Scholar
• Yuan L, Siegel M, Choi K, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene. 2007 Apr 19;26(18):2563–2573.
   PubMed Web of Science ®Google Scholar
• Katt WP, Antonyak MA, Cerione RA. The diamond anniversary of tissue transglutaminase: a protein of many talents. Drug Discov Today. 2018 Mar;23(3):575–591.
   PubMed Web of Science ®Google Scholar
• Espitia Pinzon N, van Mierlo H, de Jonge JC, et al. Tissue transglutaminase promotes early differentiation of oligodendrocyte progenitor cells. Front Cell Neurosci. 2019;13:281.
   PubMed Web of Science ®Google Scholar
• Sestito C, Breve JJP, Bol J, et al. Tissue Transglutaminase contributes to myelin phagocytosis in interleukin-4-treated human monocyte-derived macrophages. Cytokine. 2020;128:155024.
   PubMed Web of Science ®Google Scholar
• Sestito C, Leurs CE, and Steenwijk MD, et al. Tissue Transglutaminase expression associates with progression of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Jul;8(4).
   PubMed Web of Science ®Google Scholar
• Ientile R, Caccamo D, Marciano MC, et al. Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci Lett. 2004 Jun 10;363(2):173–177.
   PubMed Web of Science ®Google Scholar
• Feola J, Barton A, Akbar A, et al. Transglutaminase 2 modulation of NF-kappaB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury. Brain Res. 2017 Aug 1;1668:1–11.
   PubMed Web of Science ®Google Scholar
• Shi W, Que Y, Lv D, et al. Overexpression of TG2 enhances the differentiation of ectomesenchymal stem cells into neuronlike cells and promotes functional recovery in adult rats following spinal cord injury. Mol Med Rep. 2019 Sep;20(3):2763–2773.
   PubMed Web of Science ®Google Scholar
• Yunes-Medina L, Paciorkowski A, Nuzbrokh Y, et al. Depletion of transglutaminase 2 in neurons alters expression of extracellular matrix and signal transduction genes and compromises cell viability. Mol Cell Neurosci. 2018;86:72–80.
   PubMed Web of Science ®Google Scholar
• Gundemir S, Monteagudo A, Akbar A, et al. The complex role of transglutaminase 2 in glioblastoma proliferation. Neuro Oncol. 2017 Sep 2;19:208–218.
   PubMed Web of Science ®Google Scholar
• Elahi A, Emerson J, Rudlong J, et al. Deletion or inhibition of astrocytic transglutaminase 2 promotes functional recovery after spinal cord injury. BIORXIV-2021-460455v1. 2021:under review.
   Google Scholar
• Baillie TA. Targeted Covalent Inhibitors for Drug Design. Angew Chem Int Ed Engl. 2016 Oct 17;55(43):13408–13421.
   PubMed Web of Science ®Google Scholar
• Klock C, Herrera Z, Albertelli M, et al. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2. J Med Chem. 2014 Nov 13;57(21):9042–9064.
   PubMed Web of Science ®Google Scholar
• McEwen DP, Gee KR, Kang HC, et al. Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins. Anal Biochem. 2001 Apr 1;291(1):109–117.
   PubMed Web of Science ®Google Scholar
• Jang TH, Lee DS, Choi K, et al. Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site. PloS One. 2014;9(9):e107005.
   PubMed Web of Science ®Google Scholar
• Arrasate M, Finkbeiner S. Protein aggregates in Huntington’s disease. Exp Neurol. 2012 Nov;238(1):1–11.
   PubMed Web of Science ®Google Scholar
• Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012 Jan 29;15(3):349–357.
   PubMed Web of Science ®Google Scholar
• Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194–4199.
   PubMed Web of Science ®Google Scholar